Clinical Trial Update: Expanded Access to Burosumab

View source ↗

Summary

Expanded access program for burosumab is available for patients with X-linked Hypophosphatemia or Tumor-Induced Osteomalacia.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Tumor-induced Osteomalacia
• X-linked Hypophosphatemia

Drugs mentioned

• Crysvita (burosumab)

Snippet

Sponsor: Kyowa Kirin Co., Ltd. | Conditions: X-linked Hypophosphatemia, Tumor-Induced Osteomalacia | Status: AVAILABLE